2010 Colloquium and Annual Meeting Announced
Go to meeting summary, agenda, and registration.
The Cancer Vaccine Consortium, a program of the Cancer Research Institute, is an international association of more than 70 pharmaceutical and biotech companies and academic institutions, who share a common goal of improving patient care by making cancer vaccines part of the standard-of-care in oncology.
Member scientists, clinicians, and industry leaders exchange information with one another to analyze and establish solutions to common challenges in cancer vaccine use, development, and commercialization.
The Cancer Vaccine Consortium is establishing solutions to common challenges in cancer vaccine use, development, and commercialization.
The Consortium's membership of industrial and academic leaders across the United States and Europe complements the CRI/LICR Cancer Vaccine Collaborative's international network of academic clinical and laboratory centers. Working in parallel under the Cancer Research Institute, the two programs encompass all points along the cancer vaccine and immunotherapy development spectrum, from laboratory and clinical discovery, reagent production, and immune response monitoring, to therapeutic product development and approval.
NEWS from the Cancer Vaccine Consortium
- Cancer Vaccine Consortium Partnership Referenced in OBR Green (2010.01)
Published results from workshops organized by the Cancer Vaccine Clinical Trial Working Group (CVCTWG), a joint initiative between the Cancer Vaccine Consortium and the International Society for the Biological Therapy of Cancer (iSBTc) aimed at bringing together stakeholders in the cancer vaccine development field from academia, industry, and government to establish a new clinical trials paradigm for cancer immunotherapies, are referenced extensively in an article titled "The Ongoing Hopes and Challenges of Cancer Vaccines" that appeared in the Oncology Business Review January 2010 issue of OBR Green. The article provides a survey of the state of industry-sponsored therapeutic cancer vaccine development.
- MIATA Project Announced: Minimal Information About T cell-Based Immune Monitoring Assays (2009.10.20)
The Cancer Vaccine Consortium, in partnership with the Association for Cancer Immunotherapy (www.c-imt.org) and Stanford University, announce the launch of the MIATA Project, and invite members of the immunomonitoring community to participate in this important collaborative effort to establish minimal reporting guidelines for T cell-based immunoassays.